Stay updated on Ibrutinib and Nivolumab Trial in Hodgkin Lymphoma

Sign up to get notified when there's something new on the Ibrutinib and Nivolumab Trial in Hodgkin Lymphoma page.
Latest website image capture
Clouds background image

Latest updates to the Ibrutinib and Nivolumab Trial in Hodgkin Lymphoma page

  1. Check
    yesterday
    No Change Detected
  2. Check
    8 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.
    Difference
    0.1%
    Check dated 2025-04-30T13:57:14.000Z thumbnail image
  3. Check
    15 days ago
    No Change Detected
  4. Check
    23 days ago
    Change Detected
    Summary
    The web page has undergone significant changes, including the removal of detailed information about a Phase II trial for treating classical Hodgkin lymphoma with ibrutinib and nivolumab, while adding a new registry identifier and a revision number.
    Difference
    41%
    Check dated 2025-04-16T02:11:14.000Z thumbnail image
  5. Check
    30 days ago
    Change Detected
    Summary
    The web page has updated its version from v2.14.3 to v2.14.4, and a date has been added for March 6, 2025, while a date for March 25, 2025, has been removed.
    Difference
    0.2%
    Check dated 2025-04-08T23:52:51.000Z thumbnail image
  6. Check
    59 days ago
    Change Detected
    Summary
    The page has updated its date references, removing older dates and adding new ones for March 2025.
    Difference
    0.6%
    Check dated 2025-03-10T23:57:26.000Z thumbnail image
  7. Check
    66 days ago
    Change Detected
    Summary
    The page has been updated to reflect new trial dates for Ibrutinib and Nivolumab in treating patients with relapsed or refractory classical Hodgkin lymphoma, with the previous dates being replaced by 2025 dates.
    Difference
    2%
    Check dated 2025-03-03T22:22:33.000Z thumbnail image
  8. Check
    73 days ago
    Change Detected
    Summary
    The page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.
    Difference
    1%
    Check dated 2025-02-24T18:28:33.000Z thumbnail image

Stay in the know with updates to Ibrutinib and Nivolumab Trial in Hodgkin Lymphoma

Enter your email address, and we'll notify you when there's something new on the Ibrutinib and Nivolumab Trial in Hodgkin Lymphoma page.